<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505191</url>
  </required_header>
  <id_info>
    <org_study_id>Ze117-1-2014-01a</org_study_id>
    <nct_id>NCT02505191</nct_id>
  </id_info>
  <brief_title>Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117</brief_title>
  <official_title>A Pilot Phase I, Randomised, Open Mono-center, Multiple Dose, Two Parallel Groups Clinical Trial Investigating the Pharmacokinetics of a Prolonged-release Formulation in Comparison to an Immediate-release Formulation of St. John's Wort Extract Ze 117 in Healthy Male Volunteers Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max Zeller Soehne AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Max Zeller Soehne AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot phase I, randomised, open mono-center, two parallel group clinical trial
      investigating the pharmacokinetics of a prolonged-release formulation in comparison to an
      immediate-release formulation of St. John's wort extract Ze 117 in healthy male volunteers
      under fasting condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Half Value Duration (HVD) of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak-trough fluctuation (PTF) of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lag time of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of surrogate markers of the total extract Ze 117</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half value Duration (HVD) of hyperforin</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>7 days</time_frame>
    <description>Physical examinations, Vital signs, 12 lead ECG, Clinical chemistry Parameters, Adverse Events records</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>St. John's wort prolonged-release tablet 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>St. John's wort film coated tablets 250 mg (Remotiv N)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. John's wort prolonged-release tablet 500 mg</intervention_name>
    <arm_group_label>Test</arm_group_label>
    <other_name>Prolonged-release formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. John's wort film coated tablets 250 mg</intervention_name>
    <arm_group_label>Reference</arm_group_label>
    <other_name>Immediate-release formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian male volunteers

          -  Physically and mentally healthy as judged by means of a medical and standard
             laboratory examination

          -  BMI of between 19 and 29 kg/m2, inclusively

          -  Weight not exceeding 90 kg

          -  Non-smokers (confirmed by urine cotinine test)

          -  Informed cConsent as documented by signature

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to any ingredient of the investigational medicinal
             product

          -  Any clinically significant illnesses or clinically significant surgery within 1 year
             prior to the administration of the study medication

          -  Any surgical or medical condition which might interfere with absorption, distribution,
             metabolism or excretion of the drug

          -  Any clinically significant abnormality or abnormal laboratory test results, as judged
             by the investigator found during the medical screening

          -  Positive test of hepatitis B, hepatitis C or HIV screening (HIV antibody, Hepatitis B
             (HBsAg), Hepatitis C (HCV)

          -  ECG abnormalities (clinical significant) or vital signs abnormalities (systolic blood
             pressure lower than 90 or over 145 mmHg, diastolic blood pressure lower than 60 or
             over 95 mmHg, or heart rate less than 45 or over 100bpm) at screening

          -  History of asthma or obstructive pulmonary disease (e.g.COPD)

          -  Known photohypersensitivity.

          -  Presents or history of alcohol dependence within the last year (&gt; 40 g ethanol/d or
             more than 10 units per weeks (1unit=150 ml of wine or 360 ml of beer or 45 ml alcohol
             45%))

          -  History of drug dependence or positive results of drug screen

          -  Concomitant participation in another clinical trial within the 4 weeks prior to the
             planned first drug administration.

          -  Donation of blood or blood products within 30 days prior to the planned first drug
             administration.

          -  Treatment with any medication or topical drugs with systemic action used in the past 4
             weeks, prior to the planned first drug administration ,or 6 times the half-life of the
             respective drug, whatever is longer (excluding single use of paracetamol or ibuprofen
             up to 24 hours prior to the planned first drug administration).

          -  Suspected inability, e.g. language problems, or known or suspected non-compliance,
             e.g. non-willingness to fulfil the dietary restrictions

          -  Difficulty to swallow study medication

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons

          -  Any reason which, in the opinion of the Investigator, would prevent the subject from
             participating the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

